Popular terms

Anergy topics
Immune Response
Expression Vector
Cancer Cells
Cancer Cell
Transcription
Polypeptide
Lymphocyte
Intracellular
Immune System
Macrophage
Dendritic Cell
Dissociation
Antagonist
Type I Diabetes
Rheumatoid Factor

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Anergy patents



      

This page is updated frequently with new Anergy-related patent applications.




Date/App# patent app List of recent Anergy-related patents
01/28/16
20160024593 
 Methods and compositions related to t-cell activity patent thumbnailMethods and compositions related to t-cell activity
Embodiments concern methods and composition related to anergic t-cells in patients, such as cancer patients. T cell anergy is a hyporesponsive state induced by tcr engagement in the absence of costimulation (schwartz, 2003).
The University Of Chigaco


10/29/15
20150306146 
 Methods of treating or preventing respiratory conditions patent thumbnailMethods of treating or preventing respiratory conditions
The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an ige-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for stro-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.. .
Mesoblast, Inc.


07/30/15
20150209387 
 Method for inducing immune tolerance using non-proliferative polymer-modified allogeneic leukocytes patent thumbnailMethod for inducing immune tolerance using non-proliferative polymer-modified allogeneic leukocytes
This invention relates to cellular-based therapies for increasing the level of regulatory t cells (treg) and/or decreasing the level of pro-inflammatory t cells (th17) to induce anergy or immune tolerance. To provide these therapeutic effects, a non-proliferative allogeneic leukocyte population is contacted with another leukocyte population.
Canadian Blood Services


07/16/15
20150196597 
 Acellular pro-tolerogenic compositions for treatment/prevention of graft rejection patent thumbnailAcellular pro-tolerogenic compositions for treatment/prevention of graft rejection
This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory t cells (treg) and/or decreasing the level of pro-inflammatory t cells (th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of mirnas and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer.
Canadian Blood Services


07/02/15
20150188458 
 Piezoelectric energy harvester device with a stopper structure, system, and methods of use and making patent thumbnailPiezoelectric energy harvester device with a stopper structure, system, and methods of use and making
The present invention relates to an energy harvester device comprising an elongate resonator beam comprising a piezoelectric material, the resonator beam extending between first and second ends; a base connected to the resonator beam at the first end with the second end being freely extending from the base as a cantilever; a mass attached to the second end of the resonator beam; a package surrounding at least a portion of the second end of the resonator beam; and a stopper connected to the mass and/or the second end of the resonator beam, where the stopper is configured to prevent contact between the second end of the resonator beam and the package. Also disclosed is a system, a method of powering an electrically powered apparatus, and methods of producing an anergy harvester device..
Microgen Systems, Inc.


07/02/15
20150184279 
 Apparatus and methods for manufacturing thin-film solar cells patent thumbnailApparatus and methods for manufacturing thin-film solar cells
Improved methods and apparatus for forming thin-film layers of semiconductor material absorber layers on a substrate web. According to the present teachings, a semiconductor layer may be formed in a multi-zone process whereby various layers are deposited sequentially onto a moving substrate web..
Hanergy Hi-tech Power (hk) Limited


06/25/15
20150175658 
 Induction of tumor immunity by variants of folate binding protein patent thumbnailInduction of tumor immunity by variants of folate binding protein
The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic t-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness..
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.


06/25/15
20150174168 
 Acellular pro-tolerogenic compositions and process for making same patent thumbnailAcellular pro-tolerogenic compositions and process for making same
This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory t cells (treg) and/or decreasing the level of pro-inflammatory t cells (th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of mirnas and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer.
Canadian Blood Services


06/18/15
20150164948 
 Acellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases patent thumbnailAcellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases
This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory t cells (treg) and/or decreasing the level of pro-inflammatory t cells (th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of mirnas and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer.
Canadian Blood Services


10/30/14
20140322301 
 Mucin antigen vaccine patent thumbnailMucin antigen vaccine
Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and cd40 ligand.

08/14/14
20140227262 

Pd-1 antagonists and methods for treating infectious disease


Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid t cell mediated responses, (2) induction of t cell exhaustion, t cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other apcs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired t cell inhibition by binding to and blocking pd-1 to prevent or reduce inhibitory signal transduction, or by binding to ligands of pd-1 such as pd-l1, thereby preventing (in whole or in part) the ligand from binding to pd-1 to deliver an inhibitory signal.

03/13/14
20140073045 

Mucin antigen vaccine


Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and cd40 ligand.

01/16/14
20140017218 

Method for inducing immune tolerance using viable polymer-modified allogeneic leukocytes


This invention relates to cellular-based therapies for increasing the level of regulatory t cells (treg) and/or decreasing the level of pro-inflammatory t cells (th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition.

12/12/13
20130330294 

Serum amyloid a (saa) overrides regulatory t cells (treg) anergy


Methods and compositions are provided for inducing the proliferation of regulatory t cells. These methods find a number of uses, including, for example, treating autoimmune and rheumatoid diseases.

04/25/13
20130101626 

Mucin antigen vaccine


Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and cd40 ligand.

02/14/13
20130039935 

Induction of tumor immunity by variants of folate binding protein


The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic t-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness..

01/17/13
20130017199 

Simultaneous inhibition of pd-l1/pd-l2


Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid t cell mediated responses, (2) induction of t cell exhaustion, t cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other apcs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired t cell inhibition by simultaneously inhibiting the pd-1 ligands, pd-l1 and pd-l2.



Anergy topics: Immune Response, Expression Vector, Cancer Cells, Cancer Cell, Transcription, Polypeptide, Lymphocyte, Intracellular, Immune System, Macrophage, Dendritic Cell, Dissociation, Antagonist, Type I Diabetes, Rheumatoid Factor

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Anergy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Anergy with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.2352

753

2 - 1 - 18